Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Diagnosis & Disease Information
Higher Rate of Infections After AHCT for Multiple Myeloma Seen in India
Researchers sought to determine rates of infections for patients with multiple myeloma receiving autologous transplantation in India compared to other countries.
Suboptimal Response to Induction Therapy May Predict Poor Survival After ASCT in Multiple Myeloma
Researchers sought to determine survival outcomes of ASCT in patients with multiple myeloma who had a suboptimal response to induction therapy.
Cost and Allocation of Scarce CAR-T Therapy for Patients With Multiple Myeloma
Researchers sought to determine the allocation and cost involved with CAR-T therapy for patients with multiple myeloma.
Aphexda Approved for Stem Cell Mobilization for ASCT in Multiple Myeloma
Aphexda is expected to be available in September 2023.
Risk of Infections Higher With Bispecific Antibody Therapy for Multiple Myeloma
Researchers sought to assess and better characterize the risk of infection in patients with MM treated with bispecific antibodies.
PET Imaging After ASCT Identified Residual Disease in MM
Researchers sought to determine whether screening patients with MM after ASCT with FDG-PET would be able to identify patients with residual disease.
Carfilzomib- and Pomalidomide-Based Regimens May Not Improve Outcomes in MM After Daratumumab
Researchers sought to determine whether carfilzomib- or pomalidomide-based therapeutic regimens would improve survival in MM following daratumumab.
Melflufen Demonstrates Efficacy in LIGHTHOUSE Trial; Drug’s Future Still Unclear
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
Model Shows Promise for New Type of Engineered CAR-T Therapy in Multiple Myeloma
Researchers sought to determine whether a double-sided approach to engineered CAR-T therapy may help to prevent immune escape in patients with multiple myeloma.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...